ALMA LAUNCHES THE WORLD'S FIRST AI-ASSISTED, PROVIDER-APPROVED MEDICAL-GRADE SKINCARE SYSTEM WITH NEARLY 12 MILLION UNIQUE FORMULATIONS
At the core of Universkin by Alma is AI-assisted analysis software designed to streamline clinical decision-making. In under a minute, providers can capture a facial image, perform intelligent skin analysis, and generate a personalized formulation for approval—selected from 487,678 combinations and nearly 12 million unique outcomes—precisely tailored to each patient's skin profile and concerns. "Universkin by Alma brings medical-grade personalization to the forefront of patient care," said Lior Dayan, CEO of Alma. "By integrating advanced, science-backed ingredients with a personalized, smarter approach, we're empowering physicians to extend the impact of aesthetic care beyond the clinic and into every patient's daily routine. As the first AI-assisted system of its kind, Universkin by Alma also lays the foundation for a broader intelligent infrastructure, one designed to optimize the patient experience, elevate clinical outcomes, and transform aesthetic care into a personalized, continuous journey."
"Personalization is the future of aesthetic medicine. Every patient's skin is unique, and tailored treatments allow us to address their specific needs for the best possible results," said Lawrence Iteld, MD, a board-certified plastic surgeon at Iteld Plastic Surgery in Chicago, IL. "With Universkin by Alma, I offer more than just skincare—we deliver real, lasting skin health, customized to each patient's unique skin journey."
The Universkin by Alma system is structured around four key pillars: Cleanse, Treat, Strengthen, and Soothe, each supported by innovative product formulations featuring Complex P or patented P-HC technology:
Cleanse: Hydrating Oil Cleanser with patented P-HC technology, gently removes makeup and impurities while nourishing the skin. Treat: The Activating Serums, powered by patented P-HC technology, are at the heart of the AI-assisted personalization process—enabling providers to generate nearly 12 million unique recommendations that address eight key skin concerns: oxidative stress, texture, redness, hydration, exfoliation, oily skin, pigmentation, and impurities. Strengthen: HA Boosting Serum with Complex P technology deeply hydrates and strengthens the skin's structure. Complementing it are Barrier Nourishing Crèmes (in Light and Rich textures) with P-HC technology; these products nourish the skin barrier, tailored to suit different skin types. Soothe: The Barrier Restoring Balm with P-HC technology calms the appearance of redness, minimizing sensitivity, and reinforcing the skin barrier, especially after aesthetic treatments.
With Universkin, Alma introduces a more innovative, personalized approach to medical-grade skincare—one that delivers both efficiency and efficacy. "At our practice, we believe in inclusive, individualized care—there's no one-size-fits-all," said John Burns, MD, board-certified plastic surgeon and medical director at JOLA in Dallas, TX. "With nearly 12 million combinations of AI-assisted recommendations, Universkin by Alma allows us to tailor skincare while streamlining routines for both staff and patients."
"Universkin by Alma reflects our core value of innovation through care, offering a treatment experience that delivers personalized results," said Keith Adams, the President of Alma North America. "We're committed to ensuring our customers remain at the forefront of aesthetic medicine with solutions that cater to each patient's unique needs."
For more information about Universkin by Alma or to find a provider near you, visit www.almainc.com.
About Alma
Alma is a global leader in medical aesthetic solutions, with over 25 years of innovation. We empower practitioners to deliver safe, effective, and life-transforming treatments to their patients, utilizing state-of- the-art, clinically proven solutions such as energy-based device lasers, diagnostics, injectables, and advanced skincare. Alma's multiple award-winning products have set a new benchmark in the medical aesthetic industry, both in terms of clinical excellence and groundbreaking innovations.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malaysian Reserve
3 hours ago
- Malaysian Reserve
Elixir MD Launches Australia & New Zealand Subsidiary in Exclusive Partnership with High Tech Medical Pty. Ltd.
IRVINE, Calif. and QUEENSLAND, Australia, Aug. 1, 2025 /PRNewswire/ — ELIXIR MD, Inc., a pioneer in advanced medical technology and proprietary treatment protocols for plastic surgery, today announced the formation of its wholly owned subsidiary in Australia and New Zealand, alongside an exclusive partnership with High Tech Medical Pty Ltd. to launch the ELIXIR MD™ device across the region. Ewan Mohammed, CEO of ELIXIR MD, Inc., stated:'We're proud to join forces with High Tech Medical—Australia and New Zealand's leading medical technology partner—to bring the ELIXIR MD™ device to facial surgery patients across one of the world's fastest-growing cosmetic markets. With more than 25 years of proven commitment to clinical excellence, High Tech Medical brings deep market insight and trusted relationships throughout the aesthetic medical community. Their long-standing success in introducing advanced technologies to Australians and New Zealanders makes them the ideal partner for ELIXIR MD, Inc.' Matt Moncrieff, Managing Director of High-Tech Medical Pty Ltd., added:'High Tech Medical is proud to work exclusively with ELIXIR MD, Inc., Ewan and the entire team have demonstrated a clear commitment to innovation and to reshaping the perioperative care model in plastic surgery. The ELIXIR MD™ device and its proprietary treatment protocols represent a new gold standard in post-surgical recovery by significantly reducing patient downtime and improving outcomes.' Australia and New Zealand: A Rising Market for Surgical Innovation Australian cosmetic surgery market reached approximately $1.8B in 2024, with expected growth to $3.9B by 2033, reflecting a CAGR of ~9.3% (IMARC Group, Rentech Digital). Facial cosmetic surgery—the category where ELIXIR MD™ is uniquely focused—is the fastest-growing segment of the cosmetic surgery market in Australia, with a projected CAGR of approximately 14.1% through 2030 (Grand View Research). Demand for face and eyelid surgeries (e.g. blepharoplasty, facelifts) is rising sharply in Australia and New Zealand, in key part driven by post-weight loss volume depletion and rejuvenation surgery (Daily Telegraph). About High Tech Medical Pty in 1999, High Tech Medical is one of the most respected providers of specialist aesthetic medical devices across Australia and New Zealand. With over two decades of leadership, the company has introduced breakthrough technologies that support minimally invasive treatments, reduce patient risk and downtime, and improve clinical outcomes. High Tech Medical is known for its consultative approach—helping practitioners select and integrate complex, high-performance systems into their practices with confidence. About ELIXIR MD, in Irvine, California, ELIXIR MD, Inc. is a medical technology company redefining recovery in plastic surgery through non-invasive, perioperative innovations. Now operating in 18 markets—including a wholly owned subsidiary in Australia and New Zealand—our FDA-cleared ELIXIR MD™ technology is built to support faster healing and better outcomes for surgeons and their patients worldwide.
Malaysian Reserve
13 hours ago
- Malaysian Reserve
ASPIRE for Lung Cancer launches the APAC Lung Cancer Policy Consensus as a regional call to action for improved lung cancer care
SINGAPORE, Aug. 1, 2025 /PRNewswire/ — On 31st July 2025, a unified consensus document for improving lung cancer care in the Asia-Pacific (APAC) region was officially launched in Singapore, marking a pivotal moment in the regional fight against lung cancer. This represents the first comprehensive consensus for the region, an evidence-based agreement between stakeholders across the healthcare ecosystem that outlines shared priorities, strategies, and recommendations to elevate the standard of lung cancer care across diverse health systems. Held on the eve of World Lung Cancer Day, the initiative involved over 43 contributors, including clinicians, academics, patient advocates, and health organisations across 14 APAC health systems. Launch Highlights and Key Voices The APAC Lung Cancer Policy Consensus was launched with keynote contributions from: Dr Mary Bussell (TriMar Strategies), who delivered an overview of the global lung cancer consensus and its relevance to regional efforts Mr Yannick Romero (Union for International Cancer Control – UICC), who contextualised the APAC consensus within the broader global lung health resolution, emphasising policy alignment and strategic integration Ms Helena Wilcox (The Lung Cancer Policy Network – LCPN), who highlighted how the APAC framework enables regional advancement in care and partnership building Mr Francis Goh (Lung Cancer Education and Advocacy for Patients – LEAP), Singapore) stressed the pivotal role of patient voices in shaping lung cancer policy and health system transformation A/Prof Herbert Loong (Asia Pacific Coalition against Lung Cancer – APCLC) and Asst Prof Yeon Wook Kim (SNU Bundang Hospital), who provided an in-depth presentation on the consensus development process, five key pillars, and concrete calls to action Lung cancer remains the leading cause of cancer-related deaths in the APAC region, and accounts for nearly 60% of global cases. With regional incidence projected to exceed 1.8 million by 2040, the need for a cohesive, regional strategy to combat the disease has never been more urgent. Furthermore, survival rates in the APAC region often lag behind global benchmarks, with five-year survival rates frequently below 20%. This fragmented landscape highlights the critical need for a coordinated approach, one that addresses the unique epidemiological, environmental, and healthcare challenges within the region. The APAC Lung Cancer Policy Consensus is the result of an extensive collaborative process involving two expert working sessions, one patient workshop and a final expert voting session, with input from patients, clinicians and academic leaders across the region. The consensus lays out a unified policy framework anchored in five core principles, all aimed at driving sustainable, equitable improvements in lung cancer prevention, detection, treatment, and stigma reduction across the region. Importantly, the APAC Consensus aligns closely with the Global Lung Cancer Consensus, which was first ratified at the 9th International Lung Cancer Network in 2023. By endorsing this global statement, the APAC region reaffirms its commitment to improving lung cancer outcomes. The Five Global Principles Anchoring the APAC Lung Cancer Policy Consensus: Improve and Expand Prevention Strengthen tobacco control, public education, and environmental risk research to prevent lung cancer across all exposure types Expand screening and diagnostic access through inclusive guidelines and innovative technologies to enable timely lung cancer detection Promote timely, affordable access to modern and personalised lung cancer treatments across diverse healthcare settings Foster cross-sectoral collaboration and advocacy to drive investment and policy reform in lung cancer care Address stigma through education and empowerment to support early diagnosis, treatment adherence, and community acceptance A Region-Specific Approach to Lung Cancer Care The APAC Lung Cancer Policy Consensus is not just a regional adaptation of global recommendations; it is a comprehensive response to the distinct challenges faced by the APAC region. Unlike Western health systems that primarily focus on smoking-related lung cancer, the APAC region must contend with a higher prevalence of lung cancer in never-smokers due to factors such as environmental pollutants, and genetic predispositions. Moreover, the region's healthcare systems are highly heterogeneous, ranging from well-resourced settings with cutting-edge cancer care to lower-resource environments building on basic cancer services. Given these disparities, a one-size-fits-all approach would be ineffective. The APAC Lung Cancer Policy Consensus presents a regionally tailored action plan that offers specific strategies and targets to improve lung cancer care and outcomes, ensuring that every health system in the region, regardless of its capacity, can make progress toward the shared goals. 'We call on policymakers, healthcare leaders, and stakeholders across the APAC region to urgently prioritise and implement policies that improve lung cancer outcomes. While the specific solutions will vary across health systems, this consensus provides a shared foundation to guide national efforts. By acting now and adapting these recommendations to local contexts, we can foster a future where healthcare systems of all sizes work together to overcome regional challenges.' said Judy Li, Consortium Manager at ASPIRE for Lung Cancer. Looking Ahead The launch of the APAC Lung Cancer Policy Consensus marks the start of a sustained regional effort to transform lung cancer care in the Asia-Pacific region. Over the coming months, ASPIRE for Lung Cancer and its partners will continue to engage with policymakers, healthcare leaders, and patient advocacy groups to ensure that the consensus principles are translated into concrete action, with measurable outcomes. Through this regional collaboration, APAC aims to drive meaningful change that will improve survival rates and quality of life for lung cancer patients across the region. For more details about the APAC Lung Cancer Policy Consensus or to learn how you can get involved in advancing lung cancer care in your region, visit About ASPIRE for Lung Cancer ASPIRE (Asia Pacific Policy Review and Engagement) for Lung Cancer is a collaborative multilateral effort focused on improving lung cancer outcomes in the Asia-Pacific region through policy reforms. We advocate for prioritising lung cancer in government action plans, aiming to drive transformative changes that enhance patient access and care. We believe in the influence of collaboration and collective action to drive positive change. We therefore work with governments, agencies, NGOs and patient groups, bringing together multi-disciplinary experts to improve health outcomes for lung cancer patients in the APAC region. CONTACT: ASPIRE for Lung Cancer,
Malaysian Reserve
a day ago
- Malaysian Reserve
BioLab Holdings, Inc. Launches Its Largest Clinical Trial to Date Evaluating Human Placental Membrane Products
Study Will Compare Four Amnion-Based Therapies Plus Standard of Care to Standard of Care Alone in Chronic Wound Management PHOENIX, July 31, 2025 /PRNewswire/ — BioLab Holdings, Inc., a Phoenix-based medical manufacturer specializing in regenerative wound care, has initiated its most comprehensive clinical trial to date. The multicenter, prospective, randomized controlled study will evaluate the efficacy of four human placental membrane (HPM) products in combination with standard of care (SOC) compared to SOC alone in the treatment of nonhealing diabetic foot ulcers (DFUs) and venous leg ulcers (VLUs). The trial, formally titled 'A Multicenter, Prospective, Randomized Controlled Modified Multi-Platform Trial Assessing the Efficacy of Human Placental Membrane Products and Standard of Care Versus Standard of Care Alone in the Management of Nonhealing Diabetic Foot Ulcers and Venous Leg Ulcers (BIOCAMP),' will enroll 650 subjects across up to 30 clinical sites nationwide. 'This study represents a major milestone in our commitment to advancing wound care through rigorous clinical research,' said Dr. Marshall Medley, chief medical officer at BioLab. 'By evaluating our full suite of amnion-based products in a real-world setting, we aim to provide clinicians with robust data to guide treatment decisions for patients with chronic wounds.' Participants will be randomized to receive one of four BioLab products—Tri-Membrane Wrap™ (HPM-1), Membrane Wrap™ (HPM-2), Membrane Wrap-Lite™ (HPM-3), or Membrane Wrap-Hydro™ (HPM-4)—in addition to SOC, or SOC alone. Treatments will be applied weekly for up to 12 weeks or until complete wound closure is achieved and confirmed two weeks later. Optional weekly visits will allow for dressing changes in both study arms. The study is designed to capture real-world clinical outcomes and support the growing body of evidence for the use of placental-derived allografts in chronic wound management. For more information on BioLab Holdings, Inc. and its regenerative wound care solutions, visit About BioLab Holdings, Holdings, Inc. is a Phoenix-based medical manufacturer focused on wound healing and regenerative medicine. Its product portfolio includes Membrane Wrap Lite™, Tri-Membrane Wrap™, Membrane Wrap™ and Membrane Wrap – Hydro™, all derived from human amniotic membrane. These minimally manipulated allografts are designed to preserve the tissue's natural properties and support healing. BioLab is committed to delivering safe, high-quality products through innovation, education and exceptional customer service. Learn more at Contact: Kwyn LowePhone: 406.314.5120Email: kwyn@
